Lore Gruenbaum, Chief Scientific Officer at Blood Cancer United, shared a post on LinkedIn:
“I am excited to announce that our Translational Research Program (TRP) is now open and accepting letters of intent through October 16, 2026.
This is one of our core biomedical research grant program supporting projects with a clear path to clinical impact, including for small molecule therapies, cell and immuno-therapies.
I’d also like to highlight a special opportunity for researchers who are based in Australia: the Snowdome Foundation, an Australian-based not-for-profit organization, is partnering with us to enhance our common goal to accelerate cures and better treatments for blood cancer patients.
You can find more information on the TRP program and on the co-funding opportunity with Snowdome Foundation.”
Other articles featuring Lore Gruenbaum on OncoDaily.